ABCL
Abcellera Biologics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.03B
P/E Ratio
—
EPS
$-0.49
Beta
0.85
52W High
$6.51
52W Low
$1.91
50-Day MA
$3.44
200-Day MA
$4.13
Dividend Yield
—
Profit Margin
-194.90%
Forward P/E
27.55
PEG Ratio
—
About Abcellera Biologics Inc
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
Fundamentals
| Revenue (TTM) | $75.13M |
| Gross Profit (TTM) | $-111.70M |
| EBITDA | $-194.93M |
| Operating Margin | -63.70% |
| Return on Equity | -14.50% |
| Return on Assets | -9.99% |
| Revenue/Share (TTM) | $0.25 |
| Book Value | $3.22 |
| Price-to-Book | 1.10 |
| Price-to-Sales (TTM) | 13.68 |
| EV/Revenue | 8.98 |
| EV/EBITDA | 5.30 |
| Quarterly Earnings Growth (YoY) | 45.90% |
| Quarterly Revenue Growth (YoY) | 788.00% |
| Shares Outstanding | $303.16M |
| Float | $206.79M |
| % Insiders | 22.75% |
| % Institutions | 37.33% |
Analyst Ratings
Consensus ($9.17 target)
1
Strong Buy6
Buy1
HoldData last updated: 4/7/2026